Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

A Double-blind, Randomized, Multicentre Trial to Compare the Anti-tumour Effects and Tolerability of a 500 mg Dose of Faslodex (Fulvestrant) Plus Arimidex (Anastrozole) With a 500 mg Dose of Faslodex(Fulvestrant) Alone and With Arimidex(Anastrozole) Alone, in Postmenopausal Women Prior to Surgery for Primary Breast Cancer

To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.

Inclusion Criteria:

• Postmenopausal women.
• Biopsy confirmation of primary breast cancer.
• Oestrogen receptor positive tumour.
• Fit for surgery within one month.
• Written informed consent to participate in the study

Exclusion Criteria:

• Previous treatment with any anti-hormonal therapy for breast cancer.
• Previous radiotherapy to the primary tumour.
• Previous chemotherapy for the primary tumour.